Novel drugs in the management of difficult-to-treat hepatitis C genotypes
Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates...
Saved in:
Main Authors: | Cartwright EJ, Miller L |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
by: Danish FA, et al.
Published: (2013) -
Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
by: Gomaa A, et al.
Published: (2017) -
Difficult bile duct cannulation: Do all roads lead to Rome?
by: Marianna Arvanitakis
Published: (2021) -
Hepatitis C in Argentina: epidemiology and treatment
by: Gaite LA, et al.
Published: (2014) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
by: JIANG Yingying
Published: (2021)